Delivering Expert Insights for making smarter decisions leading to faster therapies.
Gene Therapy Consultancy (GTC) is a cell and gene therapy consultancy founded by Dr. Rahul Kaushik and based in Magdeburg, Germany. GTC runs an AI-native consulting model that pairs a network of cell and gene therapy experts with AI.
Systematically eliminate operational inefficiencies, strategic blind spots, and costly human mistakes that burn capital and delay life-saving treatments.
To create the world's most influential Expert Network of gene therapy professionals, where individual expertise is amplified through collaborative intelligence and AI-powered insights, making every development decision smarter and every therapy pathway more efficient.
Individual experts expand their influence and earnings while contributing to a knowledge base that accelerates the entire field's progress toward life-saving treatments.
Where AI and human experts create exponentially higher collective wisdom at scale
AI helps experts deliver services faster and cheaper. Experts help AI become more accurate and smarter. Every interaction creates exponentially higher collective wisdom distributed at scale.
AI amplifies your delivery speed and reduces costs while you focus on high-value expertise. Earn more by serving more clients in less time.
Expert interactions make AI more accurate and intelligent. Real-world expertise continuously improves AI decision-making capabilities.
Every expert-AI interaction multiplies collective wisdom. Individual insights become scalable intelligence benefiting the entire network. Collective wisdom reaches anyone, anywhere, instantly. Premium expertise becomes accessible at lower costs with higher accuracy.
Developers: Better insights, lower costs, faster decisions
Patients: Faster therapies through eliminated inefficiencies
Experts: Higher income, faster delivery, expanded reach
AI: Smarter, more accurate, continuously improving
Access collective expert wisdom faster and cheaper than traditional consultancies.
Building the future of gene therapy development with deep expertise and AI innovation
Founder, CEO and Chief AI Strategist
Gene therapy expert with 10+ years of viral vector development experience across cell & gene therapy. Built viral vector platforms for CNS, retina, and liver applications. Successfully led teams and projects at clinical-stage biotechs.
LinkedIn Profile250+ professionals from 15+ countries, covering every stage of cell & gene therapy development
Expert Members
Countries
Expert Domains
Industry Verticals
Target discovery, proof-of-concept, gene selection, delivery vehicle design
Vector manufacturing, process development, quality systems, GMP readiness
IND/CTA submissions, FDA/EMA interactions, ATMP classification
Licensing, partnerships, market access, commercialization strategy
AI in drug discovery, ML for manufacturing, digital biomarkers
Novel capsids, gene editing, RNA therapeutics, next-gen manufacturing
Our experts co-create authoritative content, share specialised knowledge, and receive client projects — all coordinated through GTC's AI-powered platform.
Share insights through interviews, reviews, and collaborative reports
Get credited in published reports and tagged in LinkedIn posts to your network
Earn revenue share from reports and consulting projects generated through your contributions
Join as a CGT professional and contribute your specialised expertise to collaborative reports, earn visibility on LinkedIn, and receive revenue share linked to your contributions.
Apply as an ExpertRepresent your organisation — drug developers, enabling technology developers, service providers (CDMO, CRO), or vendors & suppliers.
Apply as an OrganisationFrequently asked questions about GTC and its founder
Dr. Rahul Kaushik founded GTC and is its CEO and Chief AI Strategist. He has 10+ years of viral vector development experience across cell and gene therapy. He built viral vector platforms for CNS, retina and liver applications.
AI helps GTC's experts deliver services, and expert input makes the AI more accurate. GTC's strategic work runs on its Intelligent Platforms, structured knowledge engines that are human-curated and continuously updated.
Experts contribute insights through interviews, reviews and collaborative reports. They are credited in published reports and tagged in LinkedIn posts. They earn revenue share from reports and consulting projects generated through their contributions.
Yes. Organisation representatives can join on behalf of drug developers, enabling technology developers, service providers such as CDMOs and CROs, or vendors and suppliers.